Antipeptide Antibody Responses following Intranasal Immunization: Effectiveness of Mucosal Adjuvants

Toxicity is a major factor limiting the development and use of potent adjuvants for human mucosally delivered vaccines. Novel adjuvant formulations have recently become available, and in the present study two have been used for intranasal immunization with a synthetic peptide immunogen (MAP-M2). Thi...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Infect Immun
Principais autores:	Olszewska, Wieslawa, Partidos, Charalambos D., Steward, Michael W.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 2000
Assuntos:	Microbial Immunity and Vaccines
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC101701/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10948106/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/iai.68.9.4923-4929.2000
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!